logo-loader
viewOpen Orphan PLC

Open Orphan awarded contract from Codagenix for COVID-19 Vaccine Trial

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing that US biotech Codagenix Inc has commissioned its hVIVO arm to carry out a first-in-human trial of a nasal vaccine for coronavirus. The phase I study of 48 healthy young adults will take place at hVIVO's state-of-the-art quarantine facility in London’s Whitechapel.

Quick facts: Open Orphan PLC

Price: 24.4 GBX

AIM:ORPH
Market: AIM
Market Cap: £175.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan signs UK government contract to development COVID-19 Human...

Open Orphan's (LON:ORPH) Chairman Cathal Friel talks to Proactive London after announcing a contract with the UK Government for the development of a COVID-19 human challenge study model. Friel explains that the company, hVIVO, is the world's leader in this sector, having safely run more human...

6 days, 6 hours ago

2 min read